Synapse Biomedical brings in $2.4 million from the Ohio Third Frontier Commission to support the next generation of its NeuRx respiratory device.
Synapse Biomedical said it landed $2.4 million in funding from the Ohio Third Frontier Commission for the next generation of its NeuRx technology.
The NeuRx device is designed to provide electrical stimulation to the muscles and nerves of the diaphragm. It won FDA approval in 2008, and again in 2011, specifically for treating chronic hypoventilation from amyotrophic lateral sclerosis.
The Oberlin, Ohio-based medical device company plans on expanding the NeuRx for use in managing critical care patients with respiratory insufficiency.